ACTRIMS Forum 2021: Long-Term Follow-Up Confirms Efficacy and Safety of Inebilizumab for Neuromyelitis Optica Spectrum Disorder
N-MOmentun open-label extension phase data demonstrate that substantial reduction in attack rate is sustained
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.